Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention

Tracy Y. Wang; Lisa McCoy; Timothy D. Henry; Mark B. Effron; John C. Messenger; David J. Cohen; Daniel B. Mark; Gregg W. Stone; Marjorie Zettler; Mandeep Singh; Gregg C. Fonarow; Eric D. Peterson

doi:10.1016/j.jacc.2013.12.012

Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention

Tracy Y. Wang, Lisa McCoy, Timothy D. Henry, Mark B. Effron, John C. Messenger, David J. Cohen, Daniel B. Mark, Gregg W. Stone, Marjorie Zettler, Mandeep Singh, Gregg C. Fonarow, Eric D. Peterson

Research output: Contribution to journal › Letter › peer-review

9 Scopus citations

Original language	English (US)
Pages (from-to)	1700-1702
Number of pages	3
Journal	Journal of the American College of Cardiology
Volume	63
Issue number	16
DOIs	https://doi.org/10.1016/j.jacc.2013.12.012
State	Published - Apr 29 2014
Externally published	Yes

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacc.2013.12.012

Cite this

Wang, T. Y., McCoy, L., Henry, T. D., Effron, M. B., Messenger, J. C., Cohen, D. J., Mark, D. B., Stone, G. W., Zettler, M., Singh, M., Fonarow, G. C., & Peterson, E. D. (2014). Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention. Journal of the American College of Cardiology, 63(16), 1700-1702. https://doi.org/10.1016/j.jacc.2013.12.012

Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention. / Wang, Tracy Y.; McCoy, Lisa; Henry, Timothy D. et al.
In: Journal of the American College of Cardiology, Vol. 63, No. 16, 29.04.2014, p. 1700-1702.

Research output: Contribution to journal › Letter › peer-review

Wang, TY, McCoy, L, Henry, TD, Effron, MB, Messenger, JC, Cohen, DJ, Mark, DB, Stone, GW, Zettler, M, Singh, M, Fonarow, GC & Peterson, ED 2014, 'Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention', Journal of the American College of Cardiology, vol. 63, no. 16, pp. 1700-1702. https://doi.org/10.1016/j.jacc.2013.12.012

@article{4d599ea892c54f1c9ad0c62ec20e8b2d,

title = "Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention",

author = "Wang, {Tracy Y.} and Lisa McCoy and Henry, {Timothy D.} and Effron, {Mark B.} and Messenger, {John C.} and Cohen, {David J.} and Mark, {Daniel B.} and Stone, {Gregg W.} and Marjorie Zettler and Mandeep Singh and Fonarow, {Gregg C.} and Peterson, {Eric D.}",

note = "Funding Information: Please note: The TRANSLATE-ACS study ( NCT01088503 ) is sponsored by Daiichi Sankyo and Lilly USA. The Duke Clinical Research Institute is the coordinating center for this study, which represents a collaborative effort with the American College of Cardiology. The authors thank Erin Hanley, MS, for her editorial contributions to this paper. Ms. Hanley did not receive compensation for her assistance, apart from her employment at the institution where this study was conducted. Dr. Wang has received research grant support (to institution) from Eli Lilly, Daiichi Sankyo, Gilead Sciences, GlaxoSmithKline, American College of Cardiology, and American Society of Nuclear Cardiology (all significant); and educational activities or lectures for AstraZeneca and the American College of Cardiology (both modest). Dr. Effron is an employee of Eli Lilly; and a shareholder of Lilly, USA. Dr. Cohen has received consulting services for Eli Lilly, Daiichi Sankyo, and AstraZeneca; and research grant support (to institution) for Eli Lilly and AstraZeneca. Dr. Mark has received research funding from Eli Lilly and Medtronic (significant). Dr. Stone is a consultant to Boston Scientific, Eli Lilly, Daiichi Sankyo, and AstraZeneca (all modest). Dr. Zettler is an employee of Eli Lilly. Dr. Fonarow is a consultant to Novartis (significant) and Janssen (modest). Dr. Peterson has received research funding for the American College of Cardiology, American Heart Association, Eli Lilly, Janssen, and Society of Thoracic Surgeons (all significant); and consulting (including continuing medical education) for Merck (modest), Boehringer Ingelheim, Genentech, Janssen, and Sanofi-Aventis (all significant). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",

year = "2014",

month = apr,

day = "29",

doi = "10.1016/j.jacc.2013.12.012",

language = "English (US)",

volume = "63",

pages = "1700--1702",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier USA",

number = "16",

}

TY - JOUR

T1 - Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention

AU - Wang, Tracy Y.

AU - McCoy, Lisa

AU - Henry, Timothy D.

AU - Effron, Mark B.

AU - Messenger, John C.

AU - Cohen, David J.

AU - Mark, Daniel B.

AU - Stone, Gregg W.

AU - Zettler, Marjorie

AU - Singh, Mandeep

AU - Fonarow, Gregg C.

AU - Peterson, Eric D.

N1 - Funding Information: Please note: The TRANSLATE-ACS study ( NCT01088503 ) is sponsored by Daiichi Sankyo and Lilly USA. The Duke Clinical Research Institute is the coordinating center for this study, which represents a collaborative effort with the American College of Cardiology. The authors thank Erin Hanley, MS, for her editorial contributions to this paper. Ms. Hanley did not receive compensation for her assistance, apart from her employment at the institution where this study was conducted. Dr. Wang has received research grant support (to institution) from Eli Lilly, Daiichi Sankyo, Gilead Sciences, GlaxoSmithKline, American College of Cardiology, and American Society of Nuclear Cardiology (all significant); and educational activities or lectures for AstraZeneca and the American College of Cardiology (both modest). Dr. Effron is an employee of Eli Lilly; and a shareholder of Lilly, USA. Dr. Cohen has received consulting services for Eli Lilly, Daiichi Sankyo, and AstraZeneca; and research grant support (to institution) for Eli Lilly and AstraZeneca. Dr. Mark has received research funding from Eli Lilly and Medtronic (significant). Dr. Stone is a consultant to Boston Scientific, Eli Lilly, Daiichi Sankyo, and AstraZeneca (all modest). Dr. Zettler is an employee of Eli Lilly. Dr. Fonarow is a consultant to Novartis (significant) and Janssen (modest). Dr. Peterson has received research funding for the American College of Cardiology, American Heart Association, Eli Lilly, Janssen, and Society of Thoracic Surgeons (all significant); and consulting (including continuing medical education) for Merck (modest), Boehringer Ingelheim, Genentech, Janssen, and Sanofi-Aventis (all significant). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2014/4/29

Y1 - 2014/4/29

UR - http://www.scopus.com/inward/record.url?scp=84898939004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898939004&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2013.12.012

DO - 10.1016/j.jacc.2013.12.012

M3 - Letter

C2 - 24486275

AN - SCOPUS:84898939004

SN - 0735-1097

VL - 63

SP - 1700

EP - 1702

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 16

ER -

Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this